XRAY

DENTSPLY SIRONA Inc. (DENTSPLY International Inc.) - Q1 2009 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2009. DENTSPLY International Inc. is the world's largest designer, developer, and manufacturer of professional dental products, operating in over 120 countries. The company's primary product categories include dental consumables, laboratory products, and specialty products (endodontics, implants, orthodontics). Approximately 60% of sales are generated outside the United States.

Key Financial Metrics

Note: Total Debt calculated as Notes payable/current portion of long-term debt ($25.6M) + Long-term debt ($460.8M).

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 9.6% year-over-year. Excluding precious metal content, sales declined 6.2%. The decline was driven primarily by a 6.9% negative impact from currency translation (strengthening U.S. dollar) and a 3.7% decrease in internal sales due to dealer inventory reductions and soft demand.
• Profitability: Operating income fell 14.7% to $86.2 million. Gross profit margin (excluding precious metals) decreased slightly from 57.5% to 57.3%, impacted by the roll-off of inventory step-up from recent acquisitions.
• Restructuring Costs: Restructuring, impairment, and other costs increased to $1.6 million from $0.2 million in the prior year, related to global headcount reductions and facility consolidations initiated in late 2008 and early 2009.
• Cash Flow: Operating cash flow dropped significantly to $10.6 million from $30.2 million, largely due to increased inventory days (110 vs. 100) and higher tax payments.
• Debt and Liquidity: Long-term debt increased by a net $37.0 million. However, cash and cash equivalents rose to $226.3 million, supported by a net new borrowing of $55.5 million and lower capital expenditures ($14.2 million vs. $18.7 million).

Guidance, Outlook, and Risks

• Outlook: Management expects to operate below its long-term sustainable internal growth rate of 4-6% in the near future due to adverse economic conditions. However, the dental industry historically performs better than the overall economy.
• Cost Management: The company is focused on cost containment, operational efficiencies, and realizing savings from restructuring plans initiated in 2009, with full savings expected in 2010.
• Legal Proceedings: Significant ongoing litigation includes:
  • Antitrust: A concluded DOJ case resulted in an injunction preventing restrictions on tooth dealers. Private class actions regarding resale price maintenance are pending appeal.
  • Product Liability: Class action suits regarding Cavitron ultrasonic scalers (alleged misrepresentation of suitability for oral surgery and water sterility) are pending in California and Pennsylvania/New Jersey.
• Market Risks: The company faces significant exposure to foreign currency exchange rates (approx. 60% of sales outside U.S.) and commodity price fluctuations (precious metals), though it utilizes hedging strategies.

Investor Verification Checklist

• Verify the impact of the strengthening U.S. dollar on future revenue projections, given 60% of sales are international.
• Monitor the progress of dealer inventory destocking and its effect on internal sales growth in Q2 and Q3 2009.
• Review the status of pending antitrust and product liability litigation for potential future accruals or settlements.
• Assess the timeline for realizing cost savings from the 2009 restructuring plans.
• Confirm the company's ability to refinance debt maturing in May 2010, as noted in the liquidity section.